About Paratek Pharmaceuticals
Paratek Pharmaceuticals, Inc. (Paratek), formerly Transcept Pharmaceuticals, Inc. is a pharmaceutical company focused on the development and commercialization of antibacterial therapeutics based upon tetracycline chemistry. Paratek's antibacterial product candidates are omadacycline and sarecycline. Omadacycline is a broad-spectrum antibiotic for use as an empiric monotherapy for community-acquired bacterial infections, such as acute bacterial skin and skin structure infections (ABSSSI), community-acquired bacterial pneumonia (CABP) and urinary tract infections (UTI). The Company's sarecycline is a Phase III antibacterial product candidate and was previously known as WC3035. Sarecycline is designed for use in the treatment of acne and rosacea. The Company's other product candidates are tetracycline-derived, molecular entities and are designed to utilize the recognized immune-modulation, anti-inflammatory and other beneficial properties of the tetracycline class.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: Pharmaceuticals
- Exchange: NASDAQ
- Symbol: PRTK
- CUSIP: 89354M10
- Previous Close: $16.10
- 50 Day Moving Average: $15.22
- 200 Day Moving Average: $13.61
- 52-Week Range: $9.80 - $18.92
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -3.68
- P/E Growth: -0.01
- Market Cap: $364.29M
- Outstanding Shares: 22,627,000
- Beta: 1.34
- Return on Equity: -115.44%
- Return on Assets: -75.45%
Companies Related to Paratek Pharmaceuticals:
- Debt-to-Equity Ratio: 0.23%
- Current Ratio: 5.86%
- Quick Ratio: 5.86%
What is Paratek Pharmaceuticals' stock symbol?
Paratek Pharmaceuticals trades on the NASDAQ under the ticker symbol "PRTK."
Where is Paratek Pharmaceuticals' stock going? Where will Paratek Pharmaceuticals' stock price be in 2017?
7 brokerages have issued 12-month price objectives for Paratek Pharmaceuticals' shares. Their forecasts range from $23.00 to $52.00. On average, they expect Paratek Pharmaceuticals' stock price to reach $37.33 in the next twelve months.
When will Paratek Pharmaceuticals announce their earnings?
Paratek Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, February, 21st 2017.
Who owns Paratek Pharmaceuticals stock?
Paratek Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include FMR LLC (9.35%), Broadfin Capital LLC (3.47%), Interwest Venture Management Co. (2.26%), Fortress Investment Group LLC (1.92%), State Street Corp (1.05%) and Renaissance Technologies LLC (0.49%). Company insiders that own Paratek Pharmaceuticals stock include Douglas W Pagan, Evan Loh, Fund Iv LP Omega, Hbm Healthcare Investments (Ca and Michael Bigham.
Who sold Paratek Pharmaceuticals stock? Who is selling Paratek Pharmaceuticals stock?
Paratek Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Turner Investments LLC, GRT Capital Partners L.L.C. and Metropolitan Life Insurance Co. NY. Company insiders that have sold Paratek Pharmaceuticals stock in the last year include Douglas W Pagan, Evan Loh and Michael Bigham.
Who bought Paratek Pharmaceuticals stock? Who is buying Paratek Pharmaceuticals stock?
Paratek Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Interwest Venture Management Co., State Street Corp, Baird Financial Group Inc., Ellington Management Group LLC and Dynamic Technology Lab Private Ltd. Company insiders that have bought Paratek Pharmaceuticals stock in the last two years include Evan Loh, Fund Iv LP Omega and Michael Bigham.
How do I buy Paratek Pharmaceuticals stock?
Shares of Paratek Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Paratek Pharmaceuticals stock cost?
One share of Paratek Pharmaceuticals stock can currently be purchased for approximately $16.10.